Orion OYJ (OTCMKTS:ORINY) Trading Down 0.8% - Here's What Happened

Key Points

• Orion OYJ (OTCMKTS:ORINY) shares fell 0.8% during trading, with a last traded price of $40.42 and a significant increase in trading volume of 1,097% from the average.
• The company reported $0.33 EPS and $472.57 million in revenue for the last quarter, with analysts predicting 1.18 EPS for the current fiscal year.
• Orion OYJ has a market capitalization of $11.41 billion and a favorable financial position, indicated by a current ratio of 3.79 and a debt-to-equity ratio of 0.27.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) was down 0.8% on Tuesday . The company traded as low as $40.42 and last traded at $40.42. Approximately 1,924 shares traded hands during trading, an increase of 1,097% from the average daily volume of 161 shares. The stock had previously closed at $40.76.

Orion OYJ Trading Up 0.3%

The stock has a market capitalization of $11.52 billion, a P/E ratio of 27.76 and a beta of 0.10. The company has a current ratio of 1.86, a quick ratio of 2.27 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $37.38 and a 200 day moving average price of $31.68.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. The firm had revenue of $472.57 million during the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. On average, research analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.